Patient characteristics (n=25)
| N (%) | |
| Age, median (range) | 70 (46–84) |
| Sex, male/female | 18/7 (72/28) |
| Smoking history, yes/no | 19/6 (76/24) |
| ECOG-PS, 0/1/2 | 12/12/1 (48/48/4) |
| Histology, ad/sq/NOS | 16/8/1 (64/32/4) |
| Stage, III/IV/recurrence | 5/17/3 (20/68/12) |
| Driver mutation, EGFR/ALK/none | 2/1/22 (8/4/88) |
| Number of previous regimen, 1/2/3/≥4 | 11/8/4/2 (44/32/16/8) |
| PD-L1 expression, TPS <1%/1%–49%/≥50%/unknown | 9/8/3/5 (36/32/12/20) |
| Confirmed response: CR/PR/SD/PD | 1/8/7/9 (4/32/28/36) |
ad, adenocarcinoma; ALK, anaplastic lymphoma kinase; CR, complete response; ECOG-PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; NOS, not otherwise specified; PD, progressive disease; PR, partial response; SD, stable disease; sq, squamous cell carcinoma.